Overview
Bajaj Healthcare Limited is a major pharmaceutical manufacturer specializing in APIs, finished dosage forms, and nutraceuticals. It operates 20 state-of-the-art manufacturing facilities and exports products to over 60 countries.
In FY 2025, Bajaj Healthcare achieved a total income of Rs 562.01 Cr, showcasing resilience amid challenging market conditions. The company maintains a net worth of Rs 486.39 Cr, illustrating a sound financial position.
Bajaj Healthcare's strategic acquisition of Genrx Pharmaceuticals Private Limited marks a significant growth step, reinforcing its market presence and operational capacities.
With a robust R&D pipeline, Bajaj Healthcare focuses on peptide synthesis and aims commercialization by March 2026, emphasizing its commitment to innovation and expanding global demand.
Its CDMO partnership with UK/EU clients highlights Bajaj Healthcare's strategic move to enhance international collaborations, ensuring a foothold in lucrative markets and exclusive medicinal manufacturing.
- Sector
Pharmaceuticals
- Industry
Pharmaceuticals - Indian - Bulk Drugs & Formln M/S
- Market Cap
1,026 Cr
- Volatility
High Risk
- P/E Ratio
20.8
- Industry P/E
28.4
- PEG Ratio
0.1
- P/B Ratio
2.1
- 52W High
744.90
- 52W Low
312.05
Financial Ratios
Sales CAGR
- 1Y
- 14.61%
- 3Y
- -7.24%
- 5Y
- 5.76%
- 10Y
- 10.39%
Profit CAGR
- 1Y
- 147.14%
- 3Y
- -15.59%
- 5Y
- 11.21%
- 10Y
- 20.19%
ROE
- TTM
- 10.52%
- 3Y
- -0.11%
- 5Y
- 9.02%
- 10Y
- 9.69%
ROCE
- TTM
- 10.52%
- 3Y
- 13.16%
- 5Y
- 19.35%
- 10Y
- 19.35%
Actions
AI Mode
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Ask AI
